Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ORIC logo ORIC
Upturn stock ratingUpturn stock rating
ORIC logo

Oric Pharmaceuticals Inc (ORIC)

Upturn stock ratingUpturn stock rating
$10.15
Last Close (24-hour delay)
Profit since last BUY27.35%
upturn advisory
Consider higher Upturn Star rating
BUY since 22 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ORIC (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

12 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $18.9

1 Year Target Price $18.9

Analysts Price Target For last 52 week
$18.9Target price
Low$3.9
Current$10.15
high$14.67

Analysis of Past Performance

Type Stock
Historic Profit -3.79%
Avg. Invested days 31
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 878.60M USD
Price to earnings Ratio -
1Y Target Price 18.9
Price to earnings Ratio -
1Y Target Price 18.9
Volume (30-day avg) 12
Beta 1.48
52 Weeks Range 3.90 - 14.67
Updated Date 06/30/2025
52 Weeks Range 3.90 - 14.67
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.88

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -30.87%
Return on Equity (TTM) -48.45%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 678091631
Price to Sales(TTM) -
Enterprise Value 678091631
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.13
Shares Outstanding 85218400
Shares Floating 46267677
Shares Outstanding 85218400
Shares Floating 46267677
Percent Insiders 7.93
Percent Institutions 102.7

Analyst Ratings

Rating 4
Target Price 18.9
Buy 2
Strong Buy 10
Buy 2
Strong Buy 10
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Oric Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Oric Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies to overcome resistance in cancer. Founded in 2014, it went public in 2020 (ORIC). Its focus is on precision medicine approaches.

business area logo Core Business Areas

  • Oncology Drug Development: Focuses on developing small-molecule therapeutics targeting mechanisms of therapeutic resistance.

leadership logo Leadership and Structure

The company is led by Jacob Chacko, MD, as CEO, with a management team experienced in oncology drug development. The organizational structure is typical for a biopharmaceutical company, with R&D, clinical development, and business operations functions.

Top Products and Market Share

overview logo Key Offerings

  • Lerociclib (ORIC-101): An investigational glucocorticoid receptor antagonist targeting prostate cancer and other solid tumors. Currently in clinical trials. Early clinical trial data is being assessed. Competitors include companies developing novel oncology therapies, especially those targeting similar pathways.
  • ORIC-533: An investigational inhibitor of polycomb repressive complex 2 (PRC2) targeting multiple myeloma. Currently in clinical trials. Early clinical trial data is being assessed. Competitors include companies developing treatments for multiple myeloma.
  • ORIC-944: An investigational EHMT inhibitor targeting prostate cancer. Currently in clinical trials. Early clinical trial data is being assessed. Competitors include companies developing treatments for prostate cancer.

Market Dynamics

industry overview logo Industry Overview

The oncology therapeutics market is large and rapidly growing, driven by an aging population and advances in cancer biology. The market is competitive and highly regulated.

Positioning

Oric is positioned as a precision medicine company focused on overcoming resistance mechanisms in cancer. Its competitive advantage lies in its novel drug targets and experienced management team.

Total Addressable Market (TAM)

The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars globally. Oric is targeting specific subsets of cancer patients with resistance mechanisms, representing a significant portion of the overall TAM.

Upturn SWOT Analysis

Strengths

  • Novel drug targets
  • Experienced management team
  • Strong preclinical data
  • Focus on precision medicine

Weaknesses

  • Early-stage clinical development
  • High cash burn rate
  • Reliance on clinical trial success
  • Limited commercial infrastructure

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new cancer indications
  • Acquisition by a larger company

Threats

  • Clinical trial failures
  • Competition from other drug developers
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • MRTX
  • ARRY
  • GILD
  • BMY
  • PFE

Competitive Landscape

Oric competes with other biotechnology and pharmaceutical companies developing oncology therapies. Its success depends on demonstrating superior efficacy and safety in clinical trials.

Growth Trajectory and Initiatives

Historical Growth: Oric's historical growth is characterized by preclinical and early clinical development activities.

Future Projections: Future growth depends on the success of its clinical trials. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include advancing lerociclib, ORIC-533, and ORIC-944 into later-stage clinical trials.

Summary

Oric Pharmaceuticals is an early-stage biotech company focused on developing novel cancer therapies. Its success is heavily reliant on positive clinical trial data and securing partnerships. The company faces significant risks, including clinical trial failures and competition but it is positioned well with it's pipeline.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies is highly speculative and involves significant risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Oric Pharmaceuticals Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2020-04-24
President, CEO & Director Dr. Jacob M. Chacko M.B.A., M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 122
Full time employees 122

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. The company develops ORIC-533, an orally bioavailable small molecule inhibitor of CD73; and ORIC-613, a small molecule therapeutic intended to address a mechanism of innate resistance found in a subset of breast cancers. It has clinical development collaboration agreement for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer Inc.; a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.